课题基金 / 基金详情

Tackling the two greatest obstacles to Tuberculosis elimination: Treatment of latent infection and drug resistant disease.

Tackling the two greatest obstacles to Tuberculosis elimination: Treatment of latent infection and drug resistant disease.
解决消除结核病的两个最大障碍：潜伏感染的治疗和耐药性疾病。
批准号：
311618
负责人：
Menzies Richard
金额：
$575.5万
依托单位：
Research Institute of the McGill University Health Centre
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2014
资助国家：
加拿大
项目状态：
已结题
起止时间：
2014-09-01 至 2021-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=311618&lang=en
关键词：
Cost Effectiveness Analysis Drug Resistance Infectious Disease Modeling Latent Tuberculosis Randomized Trial Systematic Reviews And Meta-Analyses Tuberculosis Tuberculosis Prevention Tuberculosis Treatment

项目摘要

项目成果

Menzies Richard的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
<html> <body> <p>Tuberculosis (TB) remains a leading infectious cause of morbidity and death worldwide, and an important problem among the foreign born and indigenous populations in Canada. To achieve the goal of &lsquo;ending TB&rsquo;, announced by He
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Canada Research Chair - Tier 1
  • 批准号：
    415507
  • 项目类别：
  • 资助金额：
    $101.99万
  • 财政年份：
    2019
  • 负责人：
    Menzies Richard
  • 依托单位：
    McGill University
Religious communities to end TB (ReCET)
  • 批准号：
    372880
  • 项目类别：
    Miscellaneous Programs
  • 资助金额：
    $1.42万
  • 财政年份：
    2017
  • 负责人：
    Menzies Richard
  • 依托单位：
    Stellenbosch University (South Africa)
Evaluation of potential biomarkers of successful treatment of latent tuberculosis
A randomized trial to compare effectiveness of 4 months Rifampin (4 RIF) with 9 months Isoniazid (9 INH) in the prevention of active TB in children: The P4v9 Trial
海外基金